选择性5-羟色胺再摄取抑制剂与重症患者谵妄发生率的关系:一项系统评价
该系统评价检索PubMed、Scopus、Embase、PsycInfo、ProQuest Central及参考文献,纳入18岁以上需ICU监护且住院期间使用SSRI的成人研究,结局为谵妄和/或不良事件。两名研究者独立提取数据、评估偏倚风险,采用美国国家心肺血液研究所/美国国立卫生研究院研究质量评估工具及TREND清单评价质量,按GRADE标准分析,并按PRISMA清单设计与报告。结论为:既往处方SSRI的患者停用SSRI与谵妄发生率或表现为谵妄的撤药症状增加相关;在重症情况下继续用药可能减轻谵妄风险;对ICU入院前未使用SSRI的患者,SSRI对谵妄的影响需进一步研究。
要点
- 既往处方SSRI的重症患者,停用SSRI与谵妄发生率或表现为谵妄的撤药症状增加相关。
- 在重症情况下继续使用SSRI可能减轻谵妄风险。
- 对ICU入院前未使用SSRI的患者,SSRI对谵妄的影响需进一步研究。
- 该系统评价纳入18岁以上需ICU监护且住院期间使用SSRI的成人研究,结局为谵妄和/或不良事件。
适用人群与场景
- 18岁及以上、因危重症需ICU监护、住院期间使用SSRI的成人患者。
研究设计与关键结果
- 系统评价检索PubMed、Scopus、Embase、PsycInfo、ProQuest Central及参考文献列表和相关系统评价中的补充研究。
- 纳入标准为18岁及以上、因危重症需ICU监护、住院期间使用SSRI的成人研究,且报告谵妄和/或不良事件作为结局。
- 两名团队成员将数据提取至证据表并讨论综合,提取内容包括研究人群、对照或比较组类型、暴露、主要和次要结局指标、结果及意义。
- 采用美国国家心肺血液研究所和美国国立卫生研究院公开网站提供的研究质量评估工具及TREND清单评价文章质量并分析偏倚。
- 两名评价者分析研究的偏倚风险,分析遵循Cochrane系统评价使用的GRADE标准,并按PRISMA清单设计和报告研究。
- 结论:既往处方SSRI的患者停用SSRI与谵妄发生率或表现为谵妄的撤药症状增加相关;在重症情况下继续这些药物可能减轻谵妄风险;对ICU入院前未使用SSRI的患者,SSRI对谵妄的影响需进一步研究。
证据类型、等级与局限
- 证据类型:系统评价。
- 采用美国国家心肺血液研究所和美国国立卫生研究院研究质量评估工具及TREND清单评价质量,按GRADE标准分析,并按PRISMA清单报告。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对既往处方SSRI的重症患者,停用SSRI与谵妄发生率或表现为谵妄的撤药症状增加相关,继续用药可能减轻谵妄风险。
- 作者认为,对ICU入院前未使用SSRI的患者,SSRI对谵妄的影响需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the: 1) correlation between the maintenance or cessation of selective serotonin reuptake inhibitors (SSRIs) during hospitalization and the incidence of delirium among critically ill patients; 2) evaluate the effectiveness of utilizing SSRIs as a potential intervention for managing delirium in critically ill adults; and 3) evaluate the effects of continuing SSRIs in patients who were previously prescribed these medications on incidence of delirium or withdrawal symptoms manifesting as delirium.
DATA SOURCES: PubMed, Scopus, Embase, PsycInfo, and ProQuest Central, and additional studies identified from reference lists and relevant systematic reviews.
STUDY SELECTION: Studies included adults 18 years old and older with critical illness necessitating ICU care administered SSRIs during their hospital stay, where delirium and/or adverse effects were reported as outcomes.
DATA EXTRACTION: Two team members extracted data from included studies into evidence tables, which were subsequently discussed to synthesize and align the extracted findings. Extraction criteria included study population and the type of control or comparison group, exposures, primary and secondary outcome measures, results, and implications. We used Study Quality Assessment Tools provided by the National Heart, Lung, and Blood Institute and National Institutes of Health public websites along with the TREND checklist to evaluate the quality of articles and analyze for bias.
DATA SYNTHESIS: Two reviewers analyzed the studies' risk for bias. Analysis followed the Grading of Recommendations Assessment, Development, and Evaluation criteria used in Cochrane systematic reviews. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist to design and report the study.
CONCLUSIONS: The cessation of SSRIs in patients who were previously prescribed these medications is associated with an increased incidence of delirium or withdrawal symptoms manifesting as delirium. Continuing these medications in the setting of critical illness may mitigate the risk of delirium. Further investigation is warranted into the impact of SSRIs on delirium in patients not taking these medications prior to ICU admission.
参考来源
- Schwab H, Sines B, Moreton E, et al. The Association Between Selective Serotonin Reuptake Inhibitors and the Incidence of Delirium in Critically Ill Patients: A Systematic Review. Crit Care Explor. 2025. PMID: 39964698. doi:10.1097/CCE.0000000000001217
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。